-690x550.jpg)
WEDNESDAY, Nov. 6, 2024 (HealthDay News) — Women who are pregnant but who also have the ovarian cyst disorder polycystic ovary syndrome (PCOS) are at higher odds of giving birth to an underweight baby, new Norwegian research shows. The risk rises even higher if the woman with PCOS is alsoContinue Reading
TUESDAY, Nov. 5, 2024 (HealthDay News) — Poorer folks’ access to blockbuster weight-loss drugs through Medicaid remains limited, a new KFF analysis has found. Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers discovered. Under the Medicaid system, individual states areContinue Reading
FRIDAY, Nov. 1, 2024 (HealthDay News) — The GLP-1 drug semaglutide can help obese people manage debilitating knee arthritis, a new trial has found. People who received weekly injections of semaglutide — the active agent in the diabetes drug Ozempic and the weight-loss medication Wegovy — had a nearly 14%Continue Reading
FRIDAY, Nov. 1, 2024 (HealthDay News) — Hillary Fisher thinks receiving weight-loss surgery as a teenager put her on the path to a better life. Fisher is one of 260 teens who participated in a long-term study which recently concluded that weight-loss surgery can bring lasting health benefits for obeseContinue Reading
WEDNESDAY, Oct. 30, 2024 (HealthDay News) — Pancreatic cancer rates are rising in adults younger than 50, but many continue to believe it’s a disease that only affects the elderly, a new survey shows. Folks in that age range also say they wouldn’t be able to identify early signs andContinue Reading
MONDAY, Oct. 28, 2024 (HealthDay News) — The weight-loss drug Ozempic can guard against kidney disease in obese people, a new study shows. Patients taking semaglutide — the active agent in Ozempic and Wegovy — had as much as a 52% reduction in kidney damage, as measured by urine testing,Continue Reading
FRIDAY, Oct. 25, 2024 (HealthDay News) — As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim their waistlines, a new report finds. Prescriptions of this GLP-1 class of diabetes and weight-loss medications more than doubled between 2022 and 2023,Continue Reading
THURSDAY, Oct. 24, 2024 (HealthDay News) — Add Alzheimer’s disease to the list of conditions that might benefit from the revolutionary diabetes drug Ozempic, a new study says. People with type 2 diabetes taking semaglutide appeared to have a significantly lower risk of developing Alzheimer’s compared to patients taking sevenContinue Reading
THURSDAY, Oct. 24, 2024 (HealthDay News) — Expanding access to cutting-edge diabetes and weight-loss drugs like Ozempic and Zepbound could prevent more than 42,000 deaths a year in the United States, a new study claims. Obesity and all its attendant ills — type 2 diabetes, heart disease and cancer amongContinue Reading
-690x550.jpg)
THURSDAY, Oct. 17, 2024 (HealthDay News) — Weight-loss and diabetes drugs like Ozempic, Wegovy, Mounjaro or Zepbound appear to help people battle alcoholism and opioid addiction, a new study finds. People taking this class of drugs, called glucagon-like peptide-1 receptor agonists (GLP-1), have a 50% lower rate of drunkenness thanContinue Reading
WEDNESDAY, Oct. 16, 2024 (HealthDay News) — Obesity is a more powerful driver of breast cancer than previously thought, a new study suggests. About 40% of hormone-positive breast cancers in postmenopausal women might be linked to excess body fat, researchers reported Oct. 15 in the Journal of Epidemiology & CommunityContinue Reading
TUESDAY, Oct. 15, 2024 (HealthDay News) — Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the U.S. Food and Drug Administration revisits its Oct. 2 decision to remove the medicine from a national drug shortage list. What prompted the FDA to reconsider its decision? On Oct.Continue Reading
MONDAY, Oct. 14, 2024 (HealthDay News) — As with any new drug, parents and doctors may worry that the use of GLP-1 weight-loss meds by children and teens might raise psychiatric risks, including the risk for suicide and suicidal thoughts. But a new study involving more than 54,000 U.S. adolescentsContinue Reading
MONDAY, Oct. 14, 2024 (HealthDay News) — Results from a very small study suggest that a combination of the diabetes drug Ozempic and an innovative new intestinal procedure could help erase the need for insulin in folks with type 2 diabetes. The new trial hasn’t yet been published in aContinue Reading